Paracervical Versus Intracervical Lidocaine
This study has been completed.
Sponsor:
University of California, San Diego
Information provided by:
University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00816751
First received: December 31, 2008
Last updated: January 2, 2009
Last verified: January 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to estimate the efficacy of intracervical versus paracervical block on pain experienced during first trimester suction curettage without the use of preoperative cervical ripening. Because of the theoretical improved reliability of stromal block, the investigators hypothesize that intracervical block would produce lower pain scores than paracervical block at the time of cervical dilation.
| Condition | Intervention |
|---|---|
|
Abortion, Induced Pain |
Procedure: Paracervical block Procedure: Intracervical Drug: Buffered Lidocaine, vasopressin, sodium bicarbonate |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Paracervical Versus Intracervical Lidocaine for Suction Curettage: A Randomized Controlled Trial |
Resource links provided by NLM:
Drug Information available for:
Lidocaine hydrochloride
Argipressin
Lidocaine
Sodium bicarbonate
Vasopressin
U.S. FDA Resources
Further study details as provided by University of California, San Diego:
Primary Outcome Measures:
- Pain was assessed using a 10 cm linear visual analog scale (VAS) [ Time Frame: at baseline (prior to sedation), at completion of dilation, and at completion of curettage ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Details related to the procedure including degree of dilation, size of largest curette used, and any complications were also recorded. [ Time Frame: During and after the procedure ] [ Designated as safety issue: No ]
| Enrollment: | 132 |
| Study Start Date: | December 2007 |
| Study Completion Date: | February 2008 |
| Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 |
Procedure: Paracervical block
The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
Drug: Buffered Lidocaine, vasopressin, sodium bicarbonate
The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
|
| Experimental: 2 |
Procedure: Intracervical
The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
Drug: Buffered Lidocaine, vasopressin, sodium bicarbonate
The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Women presenting for elective first trimester abortion
Exclusion Criteria:
- Gestation over 12 weeks by ultrasound
- Weight less than 98 pounds
- Known allergy to lidocaine
- Known nonviable pregnancy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00816751
Locations
| United States, California | |
| Planned Parenthood | |
| San Diego, California, United States, 92101 | |
Sponsors and Collaborators
University of California, San Diego
Investigators
| Principal Investigator: | Jennifer L Mankowski, MD | UCSD |
More Information
No publications provided
| Responsible Party: | Jennifer L. Mankowski, MD, UCSD Department of Reproductive Medicine |
| ClinicalTrials.gov Identifier: | NCT00816751 History of Changes |
| Other Study ID Numbers: | ONG-08-1781 |
| Study First Received: | December 31, 2008 |
| Last Updated: | January 2, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Diego:
|
Local anesthesia Paracervical Intracervical |
Abortion Pain Local anesthesia for elective first trimester abortion |
Additional relevant MeSH terms:
|
Vasopressins Arginine Vasopressin Lidocaine Hemostatics Coagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Vasoconstrictor Agents Cardiovascular Agents |
Antidiuretic Agents Natriuretic Agents Physiological Effects of Drugs Anesthetics, Local Anesthetics Central Nervous System Depressants Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Anti-Arrhythmia Agents |
ClinicalTrials.gov processed this record on May 23, 2013